Clinical Trials Sponsored by Merck KGaA

Total 5032 results

Merck Sharp & Dohme LLC

Completed

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Varicella

United States
Merck Sharp & Dohme LLC

Completed

A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001) (Jade)

Dyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

HIV Infections | HIV
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Obstructive Sleep Apnea (OSA)

United States, Belgium
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Lung Cancer | Mesothelioma
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
Merck Sharp & Dohme LLC

Completed

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

HIV-1 Infection

Germany
Merck Sharp & Dohme LLC

Withdrawn

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms

China
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

Cancer | Pharmacokinetics

Belgium
Merck Sharp & Dohme LLC

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections
Merck Sharp & Dohme LLC

Terminated

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Acute Cough

United Kingdom
Merck Sharp & Dohme LLC

Completed

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection

Japan
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Merck Sharp & Dohme LLC

Completed

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

Hepatic Insufficiency | Antibacterial Agents

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Locally Advanced, Metastatic Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)

Sleep Initiation and Maintenance Disorders | Alzheimer Disease
Merck Sharp & Dohme LLC

Terminated

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Adenomatous Polyposis Coli
Merck Sharp & Dohme LLC

Withdrawn

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Completed

Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

Prevention of CMV Infection or Disease
Merck Sharp & Dohme LLC

Completed

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Melanoma
Merck Sharp & Dohme LLC

Completed

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Neoplasms
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

Chemotherapy-induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)

Renal Impairment | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

Intra-abdominal Infections
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Metastatic or Locally Advanced Cancer
Merck Sharp & Dohme LLC

Completed

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Single Dose Corticosteroids on Response to Allergens

Allergic Rhinitis
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Neoplasms | Cancer | Metastatic Solid Tumors | Locally Advanced Tumors
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Anesthesia, General
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Multiple Myeloma

United States, Canada, France, Israel, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)

Anesthesia, General

3

Subscribe